PortViewPortView
Virax Biolabs logo

Virax Biolabs (VRAX) Stock Analysis

NASDAQHealthcareBiotechnology

$2.53-2.69%
1-year price historyRange $2.55 – $17.20
52-week range$2.53
$2.50$21.75

What Virax Biolabs does

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.

Key metrics

Market cap
$472,161
P/E (TTM)
-0.04
EPS (TTM)
$-61.75
Beta
1.34
Dividend yield
0.00%
Revenue / share
$0.04
50-day avg
$3.21
200-day avg
$5.68
52-week high
$21.75
52-week low
$2.50
CEO
James Foster

ETFs linked to VRAX

Broad-market and Healthcare sector ETFs an investor holding Virax Biolabs is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VRAX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze VRAX in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Virax Biolabs?
Virax Biolabs trades under the ticker VRAX on NASDAQ.
Which exchange is VRAX listed on?
VRAX is listed on NASDAQ.
What sector does Virax Biolabs operate in?
Virax Biolabs is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze VRAX in a portfolio?
PortView shows VRAX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.